Takeda
Polonez II
Clinical efficacy of vedolizumab for the treatment of Crohn's disease within the Drug Program.
A PROSPECTIVE, OBSERVATIONAL STUDY INCLUDING PATIENT-REPORTED FATIGUE AND OTHER SYMPTOMS
BioStat ® ensures the smooth progress of the study and data analysis.
If you have any questions, please contact the study organizer:

BioStat Ltd.
17 Kowalczyka Street, 44-206 Rybnik
Phone: 666 069 814; email: [email protected]
eCRF.biz BioStat